TABLE 1.

Scores on Measures of Psychosocial Functioning and Quality of Life of Patients With Body Dysmorphic Disorder at Baseline and Endpoint in a 12-Week Placebo-Controlled Trial of Fluoxetine

	Baseline				Endpoint
	Fluoxetine Group (N = 31)		Placebo Group (N = 29)		Fluoxetine Group (N = 31)		Placebo Group (N = 29)		Analysis
Measure	Mean	SD	Mean	SD	Mean	SD	Mean	SD	F	df	p	Effect Sizea
Social and Occupational Functioning
Scale scoreb	56.4	9.1	55.8	9.2	71.1	17.8	60.0	15.1	8.5	1, 57	.005	.37
LIFE-RIFT scorec
Total	12.7	2.5	13.6	2.7	9.6	3.6	12.6	3.3	9.4	1, 57	.003	.42
Household duties	3.1	0.9	3.4	1.3	2.3	1.0	3.2	1.3				.38
Work	3.5	1.1	3.7	1.2	2.2	0.9	3.3	1.3				.63
Recreation	2.9	1.0	3.0	1.1	2.2	1.2	3.1	1.2				.49
Relationships with family	2.6	0.9	2.8	1.0	1.9	0.7	2.7	1.1				.40
Relationships with friends	2.7	1.2	2.5	1.2	2.3	1.2	2.5	1.2				.19
Satisfaction	3.3	0.7	3.6	0.7	2.4	1.1	3.2	1.1				.33
Medical Outcomes Study 36-Item
Short-Form Health Survey subscale score
Mental health	36.8	16.5	37.2	16.0	56.6	21.2	47.5	21.3	3.9	1, 56	.06	.40
Social functioning	39.2	24.9	35.0	21.9	54.7	31.8	52.1	27.1	0.0	1, 56	.98	.01
Role limits-emotional	25.0	29.6	33.3	41.8	44.8	43.0	43.7	39.9	0.1	1, 54	.79	.09

^aEffect size of .20 is small, .50 is medium, and .80 is large.

^bA score of 50–60 reflects moderate impairment in functioning (e.g., few friends, conflicts with peers or coworkers).

^cTotal score is based on all individual items; individual item scores range from 1 to 6, with a score of ≥2 indicating impairment.